Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Dominik Nann
Based on 1 article published since 2010
(Why 1 article?)

Between 2010 and 2020, Dominik Nann wrote the following article about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Article mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. 2016

Falletta, Simona / Partelli, Stefano / Rubini, Corrado / Nann, Dominik / Doria, Andrea / Marinoni, Ilaria / Polenta, Vanessa / Di Pasquale, Carmelina / Degli Uberti, Ettore / Perren, Aurel / Falconi, Massimo / Zatelli, Maria Chiara. ·Department of Medical ScienceSection of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy. · Pancreatic Surgery UnitPancreas Translational and Research Institute, San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. · Department of Biomedical Sciences and Public HealthPolytechnic University of Marche, Ancona, Italy. · Institut fur PathologieUniversity of Bern, Bern, Switzerland. · Department of Medical ScienceSection of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy ztlmch@unife.it. ·Endocr Relat Cancer · Pubmed #27697900.

ABSTRACT: Medical therapy of pancreatic neuroendocrine tumors (P-NET) may take advantage of Everolimus treatment. However, the extent of therapeutic response cannot be predicted. This study was aimed to identify the possible predictive markers of response to Everolimus in P-NET. We found that Everolimus reduced the cell viability and induced apoptosis in primary cultures of 6 P-NET (P-NET-R), where the proliferative and antiapoptotic effects of IGF1 were blocked by Everolimus. On the contrary, 14 P-NET primary cultures (P-NET-NR) were resistant to Everolimus and IGF1, suggesting an involvement of PI3K/AKT/mTOR pathway in the mechanism of resistance. The response to Everolimus in vitro was associated with an active AKT/mTOR pathway and seemed to be associated with a greater clinical aggressiveness. In addition, a patient sensitive to Everolimus in vitro was sensitive to this drug in vivo also and showed a positive p-AKT immunohistochemistry (IHC) at tissue level. Similarly, a patient resistant to Everolimus treatment after surgery was not sensitive to the drug in vitro and had a negative p-AKT IHC staining. Therefore, present data confirm that P-NET primary cultures may be considered a model for testing medical treatment efficacy and that IHC characterization of p-AKT might help in identifying human P-NET who can benefit from Everolimus treatment. These data encourage conducting a prospective multicenter study involving different groups of P-NET patients treated with Everolimus.